期刊导航
期刊开放获取
河南省图书馆
退出
期刊文献
+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
检索
高级检索
期刊导航
Recent advances in treatment of follicular lymphoma: efficacy of PI3Kα/δ inhibitor (TQ-B3525)
被引量：
1
原文传递
导出
摘要
The commented study reports the results of monotherapy using TQ-B3525,a novel phosphatidylinositol-3 kinase(PI3K)inhibitor developed in China,in patients with refractory/relapsed follicular lymphoma(r/r FL).
作者
Takuya Watanabe
机构地区
Department of Internal Medicine and Gastroenterology
出处
《Signal Transduction and Targeted Therapy》
SCIE
CSCD
2024年第6期2341-2343,共3页
信号转导与靶向治疗（英文）
关键词
PI3K
LYMPHOMA
TREATMENT
分类号
R733.1 [医药卫生—肿瘤]
引文网络
相关文献
节点文献
二级参考文献
0
参考文献
1
共引文献
1
同被引文献
2
引证文献
1
二级引证文献
0
参考文献
1
1
Huaqing Wang,Jifeng Feng,Yanyan Liu,Zhengzi Qian,Da Gao,Xuehong Ran,Hui Zhou,Lihong Liu,Binghua Wang,Meiyun Fang,Hebing Zhou,Zhenqian Huang,Shi Tao,Zhuowen Chen,Liping Su,Hang Su,Yu Yang,Xiaobao Xie,Huijing Wu,Ping Sun,Guoyu Hu,Aibin Liang,Zhiming Li.
Phase II study of novel orally PI3Kα/δinhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma[J]
.Signal Transduction and Targeted Therapy,2024,9(5):2193-2201.
被引量：2
共引文献
1
1
吴俣,代诗硕.
从肿瘤生物学进展探讨复发难治滤泡性淋巴瘤的识别和治疗[J]
.西部医学,2024,36(10):1405-1411.
同被引文献
2
1
中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会淋巴细胞疾病学组,中国滤泡淋巴瘤工作组,中国老年保健协会淋巴瘤专业委员会,中国抗癌协会淋巴瘤专业委员会,徐兵,黄慧强,赵海军,李小秋,林志娟.
中国滤泡性淋巴瘤诊断与治疗指南(2023年版)[J]
.中华血液学杂志,2023,44(7):529-534.
被引量：6
2
Huaqing Wang,Jifeng Feng,Yanyan Liu,Zhengzi Qian,Da Gao,Xuehong Ran,Hui Zhou,Lihong Liu,Binghua Wang,Meiyun Fang,Hebing Zhou,Zhenqian Huang,Shi Tao,Zhuowen Chen,Liping Su,Hang Su,Yu Yang,Xiaobao Xie,Huijing Wu,Ping Sun,Guoyu Hu,Aibin Liang,Zhiming Li.
Phase II study of novel orally PI3Kα/δinhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma[J]
.Signal Transduction and Targeted Therapy,2024,9(5):2193-2201.
被引量：2
引证文献
1
1
吴俣,代诗硕.
从肿瘤生物学进展探讨复发难治滤泡性淋巴瘤的识别和治疗[J]
.西部医学,2024,36(10):1405-1411.
1
程开芳,左林伟,胡芳芳,廖首生,陆相桐,李里香,黄文勇.
EBV阳性滤泡性淋巴瘤2例临床病理观察[J]
.诊断病理学杂志,2024,31(4):330-332.
2
Ying Shi,Pei-Wen Sun,Le Wang,Hong-Sheng Wang,Mei-Wen Yu,Heng Gu.
Epidemiology of Leprosy in China,2021:An Update[J]
.International Journal of Dermatology and Venereology,2024,7(1):35-39.
3
卓亚琪.
Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation[J]
.China Medical Abstracts(Internal Medicine),2024,41(2):123-123.
4
Jinhua Liang,Li Wang,Xiaodong Wang,Guohui Cui,Jianfeng Zhou,Tongyao Xing,Kaixin Du,Jingyan Xu,Luqun Wang,Rong Liang,Biyun Chen,Jian Cheng,Haorui Shen,Jianyong Li,Wei Xu.
Chidamide plus prednisone,cyclophosphamide,and thalidomide for relapsed or refractory peripheral T-cell lymphoma:A multicenter phase II trial[J]
.Chinese Medical Journal,2024,137(13):1576-1582.
5
黄荣威,贾琳,孙延成,刘一品.
十二指肠型滤泡性淋巴瘤文献复习及4例随诊报道[J]
.世界华人消化杂志,2024,32(7):538-544.
6
Yan Gao,Haixia He,Xueping Li,Liling Zhang,Wei Xu,Ru Feng,Wenyu Li,Yin Xiao,Xinxiu Liu,Yu Chen,Xiaoxiao Wang,Bing Bai,Huijing Wu,Qingqing Cai,Zhiming Li,Jibin Li,Suxia Lin,Yanxia He,Liqin Ping,Cheng Huang,Jiaying Mao,Xiujin Chen,Baitian Zhao,Huiqiang Huang.
Sintilimab(anti-PD-1 antibody)plus chidamide(histone deacetylase inhibitor)in relapsed or refractory extranodal natural killer T-cell lymphoma(SCENT):a phase Ⅰb/Ⅱ study[J]
.Signal Transduction and Targeted Therapy,2024,9(6):2765-2773.
7
Hai-Shuang Lin,Xiao-Ping Xu,Xuan-Li Zheng,Ji-Bing Wang,Su-Jie Fan,Zuo-HongWu,Su-Mian Cheng,Li-Jun Zhao,Qin-Hua Cai,Shao-Dan Zhang,Shan-Shan Liu,Ai-Guo Lyu,Ying Zhang,Hong Chen,Dan-Ni Jiang,Wu-Liang Li,Nathan Congdon,Clement C Tham,Ming-Guang He,Yuan-Bo Liang,the Malignant Glaucoma TreatmentTrial Study(MGTT)Group.
Malignant glaucoma treated by low-dose laser cycloplasty: a 1-year multicenter prospective noncomparative study[J]
.International Journal of Ophthalmology(English edition),2024,17(7):1248-1254.
8
张笑茜,王玉,吕成芳.
HDAC抑制剂西达本胺在血液恶性肿瘤中的研究进展[J]
.现代肿瘤医学,2024,32(15):2903-2909.
9
Jun Teishima,Daiki Murata,Kazuma Yukihiro,Yohei Sekino,Shogo Inoue,Tetsutaro Hayashi,Koji Mita,Yasuhisa Hasegawa,Masao Kato,Mitsuru Kajiwara,Masanobu Shigeta,Satoshi Maruyama,Hiroyuki Moriyama,Seiji Fujiwara,Akio Matsubara.
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma[J]
.Current Urology,2023(1):52-57.
10
胡豫,梅恒,李成功.
CS1-BCMA双靶CAR-T细胞治疗多发性骨髓瘤的研究进展[J]
.临床血液学杂志,2024,37(7):446-452.
Signal Transduction and Targeted Therapy
2024年 第6期
职称评审材料打包下载
相关作者
内容加载中请稍等...
相关机构
内容加载中请稍等...
相关主题
内容加载中请稍等...
浏览历史
内容加载中请稍等...
;
用户登录
登录
IP登录
使用帮助
返回顶部
